{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:23:33Z","timestamp":1792106613427,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4374-x","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T08:10:36Z","timestamp":1524816636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies"],"prefix":"10.1186","volume":"18","author":[{"given":"Elham","family":"Vosoughi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Nosrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Minor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Abendroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis Z.","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley P.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Kashani-Sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0694-0530","authenticated-orcid":false,"given":"Kevin B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"issue":"5","key":"4374_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459\u201365.","journal-title":"Lancet Oncol"},{"key":"4374_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ctrv.2016.03.003","volume":"45","author":"F Spagnolo","year":"2016","unstructured":"Spagnolo F, Picasso V, Lambertini M, Ottaviano V, Dozin B, Queirolo P. Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: a systematic review. Cancer Treat Rev. 2016;45:38\u201345.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"4374_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087\u201395.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4374_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687\u201396.","journal-title":"Cancer"},{"issue":"6","key":"4374_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ctrv.2004.05.001","volume":"30","author":"D Bafaloukos","year":"2004","unstructured":"Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004;30(6):515\u201320.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"4374_CR6","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","volume":"22","author":"KM Fife","year":"2004","unstructured":"Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22(7):1293\u2013300.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4374_CR7","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/cncr.25631","volume":"117","author":"TK Eigentler","year":"2011","unstructured":"Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117(8):1697\u2013703.","journal-title":"Cancer"},{"issue":"2","key":"4374_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","volume":"117","author":"JP Knisely","year":"2012","unstructured":"Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227\u201333.","journal-title":"J Neurosurg"},{"key":"4374_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13014-015-0553-y","volume":"10","author":"IH Chowdhury","year":"2015","unstructured":"Chowdhury IH, Ojerholm E, McMillan MT, Miller D, Kolker JD, Kurtz G, Dorsey JF, Nagda SN, Geiger GA, Brem S, et al. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Radiat Oncol. 2015;10:248.","journal-title":"Radiat Oncol"},{"issue":"1","key":"4374_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139.","journal-title":"N Engl J Med"},{"issue":"20","key":"4374_CR11","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376.","journal-title":"N Engl J Med"},{"issue":"9992","key":"4374_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444\u201351.","journal-title":"Lancet"},{"issue":"1","key":"4374_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158\u201366.","journal-title":"J Clin Oncol"},{"issue":"29","key":"4374_CR14","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","volume":"24","author":"AY Bedikian","year":"2006","unstructured":"Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen melanoma study group. J Clin Oncol. 2006;24(29):4738\u201345.","journal-title":"J Clin Oncol"},{"issue":"35","key":"4374_CR15","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"MB Atkins","year":"2008","unstructured":"Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, Eastern Cooperative Oncology G. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern cooperative oncology group. J Clin Oncol. 2008;26(35):5748\u201354.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4374_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","volume":"88","author":"JH Sampson","year":"1998","unstructured":"Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88(1):11\u201320.","journal-title":"J Neurosurg"},{"issue":"26","key":"4374_CR17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"4374_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"key":"4374_CR19","doi-asserted-by":"crossref","unstructured":"Tawbi HA, Forsyth PAJ, Algazi AP, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Gonzalez R, Lao CD, Postow MA, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. J Clin Oncol. 2017;35(15_suppl):9507. (May 20 2017)","DOI":"10.1200\/JCO.2017.35.15_suppl.9507"},{"key":"4374_CR20","doi-asserted-by":"crossref","unstructured":"Long GV, Atkinson V, Menzies AM, Lo S, Guminski AD, Brown MP, Gonzalez MM, Diamante K, Sandhu SK, Scolyer RA, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol. 2017;35(15_supple):9508. (May 20 2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.9508"},{"issue":"7","key":"4374_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863\u201373.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4374_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1179\/1743132813Y.0000000260","volume":"36","author":"KL Chaichana","year":"2014","unstructured":"Chaichana KL, Rao K, Gadkaree S, Dangelmajer S, Bettegowda C, Rigamonti D, Weingart J, Olivi A, Gallia GL, Brem H, et al. Factors associated with survival and recurrence for patients undergoing surgery of cerebellar metastases. Neurol Res. 2014;36(1):13\u201325.","journal-title":"Neurol Res"},{"issue":"1","key":"4374_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3171\/jns.2000.93.1.0009","volume":"93","author":"M Wronski","year":"2000","unstructured":"Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93(1):9\u201318.","journal-title":"J Neurosurg"},{"issue":"3","key":"4374_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3171\/2010.5.JNS1014","volume":"114","author":"DN Liew","year":"2011","unstructured":"Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, Kirkwood JM, Tarhini A, Moschos S, Lunsford LD. Outcome predictors of gamma knife surgery for melanoma brain metastases. Clinical article J Neurosurg. 2011;114(3):769\u201379.","journal-title":"Clinical article J Neurosurg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4374-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T19:14:43Z","timestamp":1556306083000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4374"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4374-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,27]]},"assertion":[{"value":"21 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol was approved by an institutional review board (\u201cSutter Health Institutional Review Board\u201d, San Francisco, CA, USA), and a waiver of patient consent was obtained prior to initiation of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"David R. minor received honoraria from Bristol-Myer Squibb and Merck; Mohammed Kashani-Sabet received research funding from Merck.; Kevin B. Kim received honoraria from Bristol-Myer Squibb, Merck, Novartis and Genentech. Institution received research grant from Bristol-Myer Squibb, Merck and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"490"}}